SCHEMBL3073987

SCHEMBL3073987

CCOc1ccc(Oc2ccc([C]=O)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 3/20 0.61
NQO1 P15559 1/20 0.58
TDP1 Q9NUW8 2/20 0.48
TSHR P16473 1/20 0.48
PARP10 Q53GL7 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
PLK1 P53350 1/20 0.43
ACACB O00763 1/20 0.43
ACACA Q13085 1/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL910859 0.94 NQO1 (0.67) LTA4HNQO1TDP1TSHRPARP10
SCHEMBL3074034 0.88 NQO1 (0.58) NQO1TDP1TSHRACACB
SCHEMBL9654773 0.84 PARP15 (0.42) LTA4HTDP1TSHRPARP10MEN1
SCHEMBL9422169 0.84 PARP15 (0.42) LTA4HTDP1TSHRPARP10MEN1
SCHEMBL12476726 0.84 NQO1 (0.82) LTA4HNQO1TDP1TSHRPARP10
SCHEMBL6285912 0.84 NQO1 (0.82) LTA4HNQO1TDP1TSHRPARP10
SCHEMBL3073500 0.84 LTA4H (0.63) LTA4HTSHRCA12CA1CA2
SCHEMBL27532039 0.82 RELA (0.65) NQO1KMT2AMAPTLMNANPC1
SCHEMBL6827504 0.80 LTA4H (0.64) LTA4HTSHRALDH1A1
SCHEMBL7282685 0.80 LTA4H (0.64) LTA4HTSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790744-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2010-09-07 US disclosed
US-20050181984-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY 2005-08-18 US disclosed
US-6916784-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-6743777-B1 TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY 2003-11-27 US disclosed
EP-0736541-B1 Cyclic hexapeptide antifungal agents LILLY CO ELI (US) 2002-11-27 EP disclosed
US-6384013-B1 HETEROCYCLIC PEPTIDE FUNGICIDES ELI LILLY AND COMPANY 2002-05-07 US disclosed
US-5965525-A FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES ELI LILLY AND COMPANY (US) 1999-10-12 US disclosed
CN-1185739-A Cyclic peptide fungicides ELI LILLY AD COMPANY (US) 1998-06-24 CN disclosed
CN-1036715-C Cyclic peptide antifungal agents and process for preparation thereof LILLY CO ELI (US) 1997-12-17 CN disclosed
US-5652213-A CYCLIC HEXAPEPTIDE FUNGICIDES, PARASITICIDES ELI LILLY AND COMPANY (US) 1997-07-29 US disclosed
US-5646111-A Cyclic peptide antifungal Agents ELI LILLY AND COMPANY (US) 1997-07-08 US disclosed
EP-0744405-A2 Cyclic peptide antifungal agents ELI LILLY AND COMPANY (US) 1996-11-27 EP disclosed
WO-1996031228-A1 CYCLIC PEPTIDE ANTIFUNGAL AGENTS ELI LILLY AND COMPANY (US) 1996-10-10 WO disclosed
EP-0736541-A1 Cyclic hexapeptide antifungal agents ELI LILLY AND COMPANY (US) 1996-10-09 EP disclosed
CN-1080926-A Cyclic peptide antifungal agents and preparation method thereof LILLY CO ELI (US) 1994-01-19 CN disclosed
EP-0561639-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 1993-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof NGLY1, HM13, PTMS LTA4H 2129/4885NQO1 4728/4885TDP1 3596/4885
US-20050181984-A1 Cyclic peptide antifungal agents and process for preparation thereof NGLY1, PTMS, HM13 LTA4H 2378/4885NQO1 4730/4885TDP1 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.